BEHANDLUNG VON AUGENERKRANKUNGEN
European patent · EP3501536 · In force
Register entry
- Publication number
- EP3501536
- Application number
- EP18202143
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Oct 15, 2012
- Published
- Jun 26, 2019
- Granted
- Dec 24, 2025
- Protection ends at the latest
- Oct 14, 2032
- Next annual fee due
- Oct 31, 2026
- IPC classes
- A61K 39/395 (2006.01)
- Priority
- US 201161546708 P 13.10.2011
- Divided from
- EP12840725
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Jan 14, 2026
Owner
- Owner
- EyePoint Pharmaceuticals, Inc., 480 Pleasant Street, Suite A-210, Watertown, MA 02472, USA → EyePoint, Inc., 480 Pleasant Street, Suite A-210, Watertown, MA 02472, USA
Published in Swissreg on 14.01.2026
- Dec 24, 2025
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 24.12.2025
Parties
Inventor
PETERS, Kevin
Cincinnati, OH 45242, US
SHALWITZ, Robert
Bexely, OH 43209, US
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.